...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors
【24h】

Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors

机译:新的4- anilinoquinazoline衍生物的设计,合成和生物学评价载氨基酸部分作为潜在EGFR激酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, a series of 4-anilinoquinazoline derivatives bearing amino acid moiety were designed, synthesized and evaluated for biological activities. The synthesized compounds were screened for anticancer activity against human hepatocellular carcinoma cell HepG2 using SRB assay. In vitro cell growth inhibition assays indicated that compound 6m exhibited moderate inhibitory activities only against human hepatocellular carcinoma cells HepG2 with IC50 of 8.3 mu M. Synthetic derivatives showed excellent selectivity, such as compound 6m demonstrated a strong inhibition of EGFR ( IC50 = 0.0032 mM), with selectivity of over 2000-fold over other kinases. Apoptosis analysis revealed that compound 6m caused obvious induction of cell apoptosis. 6m significantly down-regulated the expression of Bcl-2 and up-regulated the expression of Bax, decreased mitochondrial membrane potential ( Delta psi m), promoted the mitochondrial cytochrome c release into the cytoplasm, activated caspase-3, and finally induced apoptosis of HepG2 cells. Molecular docking indicated that compound 6m could bind well with EGFR. Therefore, compound 6m may be a potential agent for cancer therapy deserving further research. (c) 2017 Elsevier Masson SAS. All rights reserved.
机译:在该研究中,设计了一系列载氨基酸部分的4- anilinoquinazoline衍生物,用于生物活性。使用SRB测定筛选对人肝细胞癌细胞HepG2的抗癌活性的筛选。体外细胞生长抑制测定表明,化合物6M仅针对人肝细胞癌细胞HepG2的中等抑制活性,IC50为8.3μm。合成衍生物表现出优异的选择性,例如化合物6M证明EGFR的强烈抑制(IC50 = 0.0032mm) ,选择性超过2000倍的其他激酶。细胞凋亡分析显示化合物6M引起细胞凋亡的明显诱导。 6M显着下调Bcl-2的表达和上调的Bax表达,减少线粒体膜电位(Delta psi m),促进了线粒体细胞色素C释放到细胞质中,活化的Caspase-3,最终诱导凋亡hepg2细胞。分子对接表明化合物6M可以用EGFR结合。因此,化合物6M可以是癌症治疗的潜在剂,其值得进一步研究。 (c)2017年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号